Burden of drug use disorders from 1990 to 2021 and projection to 2050 in China: findings from the 2021 global burden of disease study
Authors:
Open Access
- 22 September 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1625873
Abstract
Background: Drug use disorders (DUDs) represent a major public health challenge globally, including China. This study investigated the impact of DUDs in China over the past 3 decades and examined the long-term trends in their epidemiological characteristics.Methods: Data were obtained from the 2021 Global Burden of Disease (GBD) study. The burden of DUDs was assessed through Disability-Adjusted Life Years (DALYs), Years of Life Lost (YLLs), and Years Lived with Disability (YLDs). Joinpoint analysis was used to compute the Average Annual Percentage Change (AAPC), and Age-Period-Cohort analyses were conducted to illustrate trends in the burden of DUDs. A Bayesian Age-Period-Cohort model was fitted to forecast the anticipated burden.Results: From 1990 to 2021, the Age-Standardized Incidence Rate (ASIR), Age-Standardized Prevalence Rate (ASPR), and Age-Standardized Mortality Rate (ASMR) for DUDs in China demonstrated a consistent decline, with AAPC values of −0.76% (95% confidence interval [CI]: 0.83% to −0.69%), −1.05% (95% CI: 1.25% to −0.84%), and −4.41% (95% CI: 4.75% to −4.08%), respectively. Analysis of temporal trends indicated that the ASIR and ASPR for DUDs peaked between 1990 and 2000, followed by a variable decline, with a minor uptick noted from 2015 to 2021. The age-standardized DALY rates reached their zenith during 1990–2000. Additionally, analysis by age group indicated that from 1990 to 2021, the ASIR and ASPR for DUDs were highest among individuals aged 20–24 years, followed by a fluctuating decline. Gender-based analysis indicated that throughout this period, disease burden indicators for males consistently surpassed those for females. Projections from the Bayesian Age-Period-Cohort model suggest the ASIR will increase by 3.91% annually from 2022 to 2050, with growth rates of 4.54% for males and 3.25% for females.Conclusion: Between 1990 and 2021, China experienced a decline in the overall burden of DUDs. However, high incidence and prevalence rates persist, signifying an ongoing significant impact. By 2050, both incidence and prevalence rates of drug abuse are expected to increase significantly, necessitating a focus on the male population and the development of targeted prevention and intervention strategies.Keywords
This publication has 60 references indexed in Scilit:
- Melanoma Incidence and Mortality Trends Among Patients Aged 59 Years or Younger in SwedenJAMA Dermatology, 2024
- Global trends in pharmacovigilance-related events: a 30-year analysis from the 2019 global burden of disease studyInternational Journal of Clinical Pharmacy, 2024
- Widening Gaps and Disparities in the Treatment of Adolescent Alcohol and Drug Use DisordersAmerican Journal of Preventive Medicine, 2023
- Trends of the Global Burden of Disease Attributable to Cannabis Use Disorder in 204 Countries and Territories, 1990–2019: Results from the Disease Burden Study 2019International Journal of Mental Health and Addiction, 2023
- Burden of lung cancer along with attributable risk factors in China from 1990 to 2019, and projections until 2030Journal of Cancer Research and Clinical Oncology, 2022
- Time trends and associated factors of global burden due to drug use disorders in 204 countries and territories, 1990–2019Drug and Alcohol Dependence, 2022
- Do men who have sex with men who report alcohol and illicit drug use before/during sex (chemsex) present moderate/high risk for substance use disorders?Drug and Alcohol Dependence, 2020
- Non-medical use of prescription drugs and cultural orientation among college students in ChinaDrug and Alcohol Dependence, 2018
- Trajectories of antidepressant medication before and after retirement: the contribution of socio-demographic factorsEuropean Journal of Epidemiology, 2013
- Drug Abuse in China: Past, Present and FutureCellular and Molecular Neurobiology, 2007